RANBAXY

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 12, 2012, titled "Ranbaxy opens New Manufacturing Facility in Morocco".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 06, 2012, titled "Ranbaxy Launches Atorvastatin in Germany - Agreement with Innovator allows early entry of generic before patent expiry - Synergistic Arrangement with Daiichi Sankyo Germany".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 06, 2012, titled "Ranbaxy Becomes The First Company To Launch Generic Atorvastatin in Italy, Netherlands & Sweden".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated February 23, 2012, titled "Ranbaxy Crosses $2 BN In Global Sales".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated February 21, 2012, titled "Ranbaxy Launches Atorvastatin in Australia; First Company to introduce Generic Version".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated January 26, 2012, titled "Ranbaxy Announces court Filing of Consent Decree With U.S.Food and Drug Administration".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated December 21, 2011, titled "Ranbaxy to Market Daiichi Sankyo's Innovative Products in Malaysia, Strategic Alliance Harnesses Synergies in ASEAN".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated December 21, 2011, titled "Ranbaxy Announces Consent Decree with U.S.Food And Drug Administration, takes Corrective Steps, commits to further measures."

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated December 06, 2011, titled "Ranbaxy Launches Authorized Generic Version of Caudet in the U.S.".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated December 01, 2011, titled "Ranbaxy Announces Launch of a Atorvastatin, Generic Lipitor(R), in the U.S.".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 11, 2011, titled "Ranbaxy and Daiichi Sankyo step up Community Initiatives".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 09, 2011, titled "Ranbaxy delivers strong overall base business performance and improvement in EBITDA margins".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated October 12, 2011, titled "Ranbaxy Honored with NJBIA Award For Excellence in New Jersey Business Expansion".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated October 04, 2011, titled "Ranbaxy to Extend Daiichi Sankyo Product Reach to Pharmacists Across Italy".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated September 05, 2011, titled "Ranbaxy UK Ltd. Launches esomeprazole - First approved generic version of the product to be made available in the UK".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated August 31, 2011, titled "Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative Encompassing India, Cameroon and Tanzania".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated August 12, 2011, titled "Ranbaxy introduces 'Volini Duo', a unique 2-in-1 Pain Killer, for the first time in India".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated August 05, 2011, titled "Ranbaxy's base business across geographies continues to deliver strong results".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated August 02, 2011, titled "Daiichi Sankyo and Ranbaxy to Expand Hybrid Business Model in Mexico".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated July 25, 2011, titled "Ranbaxy launches Letrozole Tablets on Day-1 in UK, Romania, France".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated July 12, 2011, titled "Ranbaxy enters into a licensing agreement with Gilead Sciences to manufacture and market three anti-HIV drugs in India and developing countries".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated May 10, 2011 titled "Ranbaxy continues to improve performance across developed and emerging markets - Sales $474 Mn, EBITDA $95 Mn, PAT $67 Mn".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated March 01, 2011, titled "Daiichi Sankyo to Leverage Ranbaxy's Network to Market Its Innovative Products in Singapore".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated February 22, 2011, titled "RANBAXY FY 2010 PAT AT $327 Mn (Rs. 14968 Mn), UP ON STRONG EARNINGS - Board Recommends Dividend of 40 Percent".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated January 31, 2011, titled "Ranbaxy and The Government of Yaroslavl Region, Russia, sign MOU for cooperation in the field of Healthcare and Medical Science".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated December 20, 2010, titled "Sonke, a Black Empowered Pharmaceutical Company, to play significant role in fight against HIV AIDS, in South Africa Wins 21.9% of Government Tender".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 30, 2010, titled "Ranbaxy launches Donepezil 5 MG and 10 MG tablets to U.S. Healthcare System".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated November 11, 2010, titled "Ranbaxy delivers continued growth in Sales and PAT for Q3, 2010".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated September 1, 2010, titled ''Ranbaxy sets up new manufacturing facility in South Africa''.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated August 12, 2010, titled ''Ranbaxy Board announces Change in Executive Leadership''.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated August 12, 2010, titled ''Ranbaxy achieves USD 1 Billion revenue and USD 282 mn PAT for H1'2010 - after record Q1 sales, Q2 growth at 22%''.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated July 21, 2010, titled ''Daiichi Sankyo to Leverage Ranbaxy's Network to Market its Innovative Antibiotic Tavanic (Levofloxacin) in Romania and South Africa''.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated July 02, 2010, titled ''Daiichi Sankyo and Ranbaxy to Integrate New Drug Research and Development System''.

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated June 10, 2010, titled "Ranbaxy Launches Antiplatelet Agent Prasugrel in India".

Ranbaxy Laboratories Limited has informed the Exchange regarding a Press Release dated June 8, 2010 titled "Ranbaxy launches Generic Atorvastatin, 'Lipogen', a cholestrol-reducing medication in South Africa".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 21, 2010, titled "Ranbaxy launches Atorvastatin, cholesterol-reducing medication into the Canadian Healthcare System".

Ranbaxy Laboratories Limited has informed the Exchange regarding a press release dated May 11, 2010 , titled "Ranbaxy delivers quarterly sales of over USD 500 MN for the first time, records profit after tax of USD 210 MN".

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 29, 2010, titled "Ranbaxy and pfenex Announce Collaboration for the Development of a Biosimilar Therapeutic Protein". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_29032010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 15, 2010, titled "Ranbaxy announces settlement of ACTOS� (Pioglitazone Hydrochloride) Patent Litigation." A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_15032010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 26, 2010, titled "Daiichi Sankyo Group to Expand its Business Scope in Japan through Establishment of Daiichi Sankyo Espha Co., Ltd". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_pr_26022010.ZIP target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 25, 2010, titled "Ranbaxy Repeats Strong Operating Performance - FY 2009 Profit Before Tax Over Rs. 1000 Crores; Global Sales at Rs. 7344 Crores". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_25022010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated February 10, 2010, titled " Daiichi Sankyo to Launch Innovator Products in Mexico through Ranbaxy, Companies to Fully Leverage the Synergistic Power of the Hybrid Business Model ". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_10022010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 19, 2010, titled "Ranbaxy Enters Vaccines Arena With The Acquisition Of Product Rights And Manufacturing Facility From Biovel". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_19012010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 04, 2010, titled " Ranbaxy Launches a New Chemical Entity (NCE), Lulifin (Luliconazole) in India- The Dermatological Product in-licensed from Summit Pharmaceuticals, Japan, strengthens Ranbaxy's skin portfolio."A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_04012010.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 29, 2009, titled "Ranbaxy to transfer stake in Ranbaxy (Guangzhou China) Limited to HNG Chembio Pharmacy Co. Ltd. " A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_pressrelease_29122009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 21, 2009, titled "Daiichi Sankyo to Leverage Ranbaxy's Presence in Africa for Marketing and Distribution Olmesartan to be launched in six African countries." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_21122009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 08, 2009, titled "Ranbaxy and Nippon Chemiphar dissolve their Joint Venture 'Nihon Pharmaceutical Industry Co. Ltd' in Japan". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_08122009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 12, 2009, titled "Ranbaxy gains WHO pre-qualification for Indinavir - 400 mg ARV capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_12112009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 26, 2009, titled "Ranbaxy Records Consistent Improvement in Operating Performance". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_26102009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 05, 2009, titled "Daiichi Sankyo to Leverage Ranbaxy's Presence in Mexico for Marketing and Distribution; New Division will bring Daiichi Sankyo's innovator products to Mexican market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_05102009.zip target=NEW> For more details click here.</a>